Phase II study evaluating the safety and efficacy of neoadjuvant leuvectin immunotherapy for the treatment of prostate cancer

Trial Profile

Phase II study evaluating the safety and efficacy of neoadjuvant leuvectin immunotherapy for the treatment of prostate cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2014

At a glance

  • Drugs Leuvectin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Vical
  • Most Recent Events

    • 28 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record..
    • 29 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top